Research programme: therapeutic cancer vaccines - Ernexa Therapeutics/National Cancer Research Center Japan
Latest Information Update: 07 Apr 2025
At a glance
- Originator IRX Therapeutics
- Developer IRX Therapeutics; National Cancer Center (Tokyo)
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer